MONTREAL, QUEBEC--(Marketwire - December 06, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that it has received two orders for the recently released preclinical optical molecular imager, Optix® MX2. The units are expected to be shipped before the end of the year. This represents the first Optix units sold by ART under its new commercial strategy.
